Valuation: Genelux Corporation

Market Cap 115M 99.73M 93.83M 85.28M 160M 11.06B 163M 1.1B 431M 5.53B 434M 424M 18.43B P/E 2026 *
-3.16x
P/E 2027 * -3.46x
Enterprise Value 115M 99.73M 93.83M 85.28M 160M 11.06B 163M 1.1B 431M 5.53B 434M 424M 18.43B EV / Sales 2026 *
-
EV / Sales 2027 * 9.48x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -
1 day+3.85%
1 week+2.59%
Current month-5.78%
1 month-5.46%
3 months-1.07%
6 months+3.36%
Current year-36.47%
1 week 2.56
Extreme 2.555
2.82
1 month 2.5
Extreme 2.5
3.08
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Executive Officer

-3,023 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%+2.59%-19.24%-87.62% 115M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.48%+14.95%+56.49%+91.80% 62.99B
-0.16%-2.73%+1.15%+484.86% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+23.12%+22.06%+1.62%-3.68% 23.3B
+2.31%+5.25%+41.47%-14.07% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+2.11%+7.16%+43.88%+152.62% 13.16B
Average +2.70%+2.72%+51.74%+169.89% 28.06B
Weighted average by Cap. +2.01%+5.48%+58.98%+164.67%

Financials

2026 *2027 *
Net sales - 12.18M 10.52M 9.9M 9M 16.92M 1.17B 17.17M 116M 45.51M 584M 45.74M 44.74M 1.94B
Net income -37.46M -32.35M -30.44M -27.67M -52.04M -3.59B -52.8M -357M -140M -1.8B -141M -138M -5.98B -38.31M -33.09M -31.13M -28.29M -53.22M -3.67B -54M -365M -143M -1.84B -144M -141M -6.11B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
19/08/26 $2.760 +6.15% 45,419
18/08/26 $2.600 -3.70% 379,006
17/08/26 $2.700 -1.46% 265,149
14/08/26 $2.740 +4.18% 462,788
13/08/26 $2.630 -2.59% 315,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.600USD
Average target price
17.50USD
Spread / Average Target
+573.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock